Last week, the Food and Drug Administration approved of the first artificial pancreas system in the world. It is actually an automated device which makes insulin delivery more easy for type 1 diabetes patients. The new method stands as a significant improvement for people who suffer from this disease.
The artificial pancreas was developed by Medtronic. The official name of the device is MiniMed 670G. The device received the approval of the authorities in the United States, but it still needs that of Europe. It is most likely that the device will be available starting next year.
What the new MiniMed 670G does it to link together two separate devices, namely a glucose monitor and an insulin pump. This means that while facilitating administration of the substance, the device also monitors the blood features of the patient.
The monitoring system warns patients how to control the level of sugar in their blood. If it is low, they have to increase it, and if it is too high, they have to reduce it. The artificial pancreas system from Medtronic is recommended to patients aged at least 14. They still have to use it while they eat, just like traditional insulin shots.
Developers tested the new product on more than one hundred volunteers. The results assured them about the efficiency of the new artificial pancreas system.
No information on the price has been officially released. However, judging by the features of the high-tech device and the advantages it brings, it could turn out to be quite expensive. Specialists estimate that the price will soar higher than five thousand dollars.
Statistics show that the number of people who suffer from diabetes in the United States has increased between 2010 and 2012. According to health reports, twenty-nine million patients had the disease four years ago. Specialists also say that Type 2 diabetes is more frequent than Type 1 and that it is more aggressive too.
However, doctors warn that Type 1 diabetes shouldn’t be underestimated. The disease affects the pancreas, which cannot provide the proper amount of insulin for the organism anymore. Patients are confined to a strict diet and regular testing for sugar level in their blood. Health experts also say that type 1 diabetes shortens the lifespan of patients by approximately twelve years.
Producers intend to improve MiniMed 670G for the comfort of patients. The device needs insulin refill every three days. Developers are also thinking about resizing the device. However, for the time being, MiniMed 670G is an excellent solution for Type 1 diabetes patients.
Image courtesy of: Wikipedia